Overview
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555350-cervical-intraepithelial-neoplasia-cin-pipeline-review-h1-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 1 molecules, respectively.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
Table of Contents
List of Figures
Introduction
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
CEL-SCI Corp
CritiTech Inc
Genexine Inc
PDS Biotechnology Corp
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
THEVAX Genetics Vaccine USA Inc
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555350-cervical-intraepithelial-neoplasia-cin-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555350-cervical-intraepithelial-neoplasia-cin-pipeline-review-h1-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 1 molecules, respectively.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
Table of Contents
List of Figures
Introduction
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
CEL-SCI Corp
CritiTech Inc
Genexine Inc
PDS Biotechnology Corp
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
THEVAX Genetics Vaccine USA Inc
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555350-cervical-intraepithelial-neoplasia-cin-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment